REDWOOD CITY, Calif., Aug. 21, 2019 /PRNewswire/ -- Genomic Health today announced that, based on results from the prospective TAILORx 1 and PlanB 2 studies, the 16 th St. Gallen International Breast ...
REDWOOD CITY, Calif., Oct. 9, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that its Oncotype DX Breast Recurrence Score ® test has been categorized as the only "preferred" ...
Title: Comprehensive comparison of prognostic signatures for breast cancer in TransATAC. Presenter: Ivana Sestak, Ph.D. Date: Friday, Dec.9, 2016: 4:15 p.m. CT. Location: S6-05; General Session 6 - ...
In the new era of personalized medicine, having more information on hand is considered the ideal situation for making more customized, and ideally, effective decisions about medical care. And in a new ...
BAAR, Switzerland, March 12, 2025--(BUSINESS WIRE)--Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced the presentation of new data further reinforcing the ...
As FOXA1, GATA3, and ER coexist in a network regulating luminal subtype A breast carcinomas, we hypothesized that tumors expressing FOXA1 and/or GATA3 will have a low recurrence score. We therefore ...
Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced the presentation of new data further reinforcing the utility of its Oncotype DX Breast Recurrence Score ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback